Omalizumab is used in treatment of:
Omalizumab recombinant humanized IgG1 kappa 149 kDa engineered grafting murine CDRs human framework binding free serum IgE constant region CH3 residues 396-409 overlapping high-affinity Fc epsilon RI alpha and low-affinity Fc epsilon RII CD23 site. Allergic asthma pathogenesis involves IgE 190 kDa produced IL-4 IL-13 driven class switching plasma cells GATA3 Th2 program binding Fc epsilon RI tetrameric alpha beta gamma2 mast cells basophils dendritic cells affinity 10^-10 M persisting weeks surface crosslinking allergen exposure two epitopes bridging IgE triggering Lyn Syk degranulation histam
Ref: FDA Xolair Omalizumab IgE Asthma Label MOA; NEJM Omalizumab Allergic Asthma 2001 Milgrom; Janeway IgE Fc epsilon RI Blockade Downregulation Mechanism.